Fat Embolization Syndrome

Course Overview

Course Outline

1. Introduction 
2. Defining FES 
   1. What Is FES?  
   2. How and Where Is FES Diagnosed?  
   3. What are the Clinical Criteria for Diagnosing FES? 
   4. What are the Common Symptoms of FES? 
   5. What Is the Average Cost for FES Treatment? 
3. Managing FES 
   1. Obtaining a Relevant Patient History 
   2. Evaluating FES 
   3. Pharmacological Methods to Manage FES 
   4. Non-Pharmacological Methods to Manage FES  
4. Nursing and Safety Considerations 
   1. What is the nurses’ role in FES patient education and management?  
   2. How can nurses identify if someone has FES?   
   3. What should patients know about FES?  
5. Upcoming Research 
   1. What research on FES exists presently? 
   2. What are some ways for people who have FES to become a part of research? 
6. Conclusion 

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In this course, we will discuss Fat Embolization Syndrome​. It will take the average learner 60 minutes to complete and awards 1 contact hours of continuing education.

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

1. Describe common clinical presentations, including severe possible symptoms, of FES 
2. List possible nursing interventions for FES 
3. Discuss the clinical criteria for FES 

Target Audience

• Registered Nurses (RN)
• Advanced Practice Registered Nurses (APRN)
• Licensed Practical Nurses (LPN/LVN)

Requirement for Completion

1. Enrollment in the course by the learner
2. Read and learn all course materials
3. Complete the course evaluation
4. Attest and testify learning of the course materials

Accreditations + Approvals

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.